KBC Group NV Cuts Position in Repligen Co. (NASDAQ:RGEN)

KBC Group NV reduced its stake in Repligen Co. (NASDAQ:RGEN) by 25.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,215 shares of the biotechnology company’s stock after selling 754 shares during the period. KBC Group NV’s holdings in Repligen were worth $319,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its position in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the last quarter. First Turn Management LLC purchased a new position in shares of Repligen during the 3rd quarter worth approximately $13,202,000. Thrivent Financial for Lutherans lifted its stake in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares during the period. Geneva Capital Management LLC grew its holdings in shares of Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock worth $20,638,000 after acquiring an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC grew its stake in Repligen by 14.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after acquiring an additional 35,115 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $159.87 on Tuesday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The business’s fifty day moving average is $154.24 and its two-hundred day moving average is $147.84. The stock has a market capitalization of $8.96 billion, a P/E ratio of -432.07, a P/E/G ratio of 4.67 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the company posted $0.23 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, research analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, HC Wainwright reduced their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $184.73.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.